MX2018003470A - Nuevo anticuerpo anti-mesotelina y composicion que comprende el mismo. - Google Patents

Nuevo anticuerpo anti-mesotelina y composicion que comprende el mismo.

Info

Publication number
MX2018003470A
MX2018003470A MX2018003470A MX2018003470A MX2018003470A MX 2018003470 A MX2018003470 A MX 2018003470A MX 2018003470 A MX2018003470 A MX 2018003470A MX 2018003470 A MX2018003470 A MX 2018003470A MX 2018003470 A MX2018003470 A MX 2018003470A
Authority
MX
Mexico
Prior art keywords
antibody
composition
same
mesothelin
novel anti
Prior art date
Application number
MX2018003470A
Other languages
English (en)
Inventor
Sik Kim Dong-
Jung Song Eun
Lee Mijung
Hee LEE Eun-
Oh Miyoung
Chan Park Jae
Kim Kisu
Kim Sujeong
Kwon Lim Hyung-
Lee Kyuhyun
Won Jongwha
Choi Soongyu
Seoub Park Young
Original Assignee
Mogam Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Inst Biomedical Res filed Critical Mogam Inst Biomedical Res
Publication of MX2018003470A publication Critical patent/MX2018003470A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo específicamente unido a mesotelina (MSLN), un ácido nucleico que codifica el anticuerpo, un vector y una célula huésped que incluye el pacido nucleico, un método para producir el anticuerpo y una composición farmacéutica para tratar cáncer o tumor incluyendo el anticuerpo como ingrediente activo. El anticuerpo unido específicamente a la mesotelina de acuerdo con la presente invención tiene una alta afinidad y especificidad para un antígeno. De manera que es posible desarrollar un anticuerpo eficazmente utilizable para el tratamiento o diagnóstico de cáncer o enfermedades tumorales.
MX2018003470A 2015-09-24 2016-09-23 Nuevo anticuerpo anti-mesotelina y composicion que comprende el mismo. MX2018003470A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150135755A KR101782487B1 (ko) 2015-09-24 2015-09-24 신규 항-메소텔린 항체 및 이를 포함하는 조성물
PCT/KR2016/010604 WO2017052241A1 (en) 2015-09-24 2016-09-23 Novel anti-mesothelin antibody and composition comprising the same

Publications (1)

Publication Number Publication Date
MX2018003470A true MX2018003470A (es) 2019-10-30

Family

ID=58386441

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003470A MX2018003470A (es) 2015-09-24 2016-09-23 Nuevo anticuerpo anti-mesotelina y composicion que comprende el mismo.

Country Status (13)

Country Link
US (1) US10851175B2 (es)
EP (1) EP3353213B1 (es)
JP (1) JP6738893B2 (es)
KR (1) KR101782487B1 (es)
CN (2) CN113603785B (es)
AU (1) AU2016328204B2 (es)
BR (1) BR112018005837A2 (es)
CA (1) CA2999237C (es)
EA (1) EA038654B1 (es)
ES (1) ES2857500T3 (es)
IL (1) IL258215B (es)
MX (1) MX2018003470A (es)
WO (1) WO2017052241A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7085708B2 (ja) 2016-06-20 2022-06-17 エフ－スター セラピューティクス リミテッド Ｌａｇ－３結合要素
LT3472207T (lt) 2016-06-20 2021-05-10 F-Star Delta Limited Surišančios molekulės, kurios suriša pd-l1 ir lag-3
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2019005208A1 (en) * 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
KR101966362B1 (ko) * 2017-10-20 2019-04-05 주식회사 녹십자 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물
TW201930355A (zh) 2017-12-19 2019-08-01 英商Ｆ星貝塔有限公司 結合物件(三)
GB201811415D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) * 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
KR102070016B1 (ko) * 2019-01-21 2020-01-29 (주)녹십자셀 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포
WO2020204305A1 (ko) * 2019-03-29 2020-10-08 주식회사 녹십자 항-메소텔린 항체, 항-cd3 항체 또는 항-egfr 항체를 포함하는 융합 단백질 및 이를 포함하는 이중 특이적 또는 삼중 특이적 항체 및 이의 용도
KR102216225B1 (ko) * 2019-06-27 2021-02-17 (주)녹십자셀 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포
KR102309543B1 (ko) * 2020-08-04 2021-10-07 주식회사 셀렌진 메소텔린에 특이적으로 결합하는 항-메소텔린 키메릭 항원 수용체
CA3133678C (en) 2020-08-04 2023-04-11 Cellengene Inc. Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin
US11883433B1 (en) 2021-05-26 2024-01-30 Cellengene Inc. Chimeric antigen receptor comprising anti-mesothelin scFv, and use thereof
KR20230005001A (ko) * 2021-06-30 2023-01-09 (주)이노베이션바이오 메소텔린 특이적 항체 및 이의 용도
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途
WO2023115528A1 (en) * 2021-12-24 2023-06-29 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against mesothelin and uses thereof
KR20240043161A (ko) * 2022-09-23 2024-04-03 국민대학교산학협력단 Grp94에 특이적으로 결합하는 항체 또는 그의 항원 결합 단편 및 약물을 포함하는 항체 약물 컨쥬게이트
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006099141A2 (en) * 2005-03-10 2006-09-21 Morphotek, Inc. Anti-mesothelin antibodies
SI2195017T1 (sl) * 2007-10-01 2015-01-30 Bristol-Myers Squibb Company Človeška protitelesa, ki vežejo mezotelin in njihova uporaba
US20100222289A1 (en) 2007-10-22 2010-09-02 Cfs Research Llc Methods for diagnosis and treatment of chronic fatigue syndrome
JP5608091B2 (ja) * 2007-11-26 2014-10-15 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 抗メソセリン抗体およびその使用
AU2009228361A1 (en) * 2008-03-27 2009-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human anti-mesothelin monoclonal antibodies
UA113838C2 (xx) * 2010-12-20 2017-03-27 Антитіло, яке зв'язує мезотелін, та імунокон'югат
WO2014004549A2 (en) * 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
EP2888282B1 (en) * 2012-08-21 2018-03-14 The U.S.A. as represented by the Secretary, Department of Health and Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
KR20150029457A (ko) 2013-09-10 2015-03-18 삼성전자주식회사 아넥신 a1에 결합하는 폴리펩타이드 및 그의 용도

Also Published As

Publication number Publication date
CA2999237C (en) 2021-07-06
IL258215B (en) 2022-07-01
EP3353213B1 (en) 2020-12-02
JP2018532401A (ja) 2018-11-08
CN108350084A (zh) 2018-07-31
BR112018005837A2 (pt) 2018-10-09
CN113603785A (zh) 2021-11-05
AU2016328204B2 (en) 2019-03-21
WO2017052241A1 (en) 2017-03-30
US10851175B2 (en) 2020-12-01
JP6738893B2 (ja) 2020-08-12
US20180346588A1 (en) 2018-12-06
EA201890796A1 (ru) 2018-10-31
CA2999237A1 (en) 2017-03-30
KR20170036503A (ko) 2017-04-03
IL258215A (en) 2018-05-31
ES2857500T3 (es) 2021-09-29
EA038654B1 (ru) 2021-09-29
CN108350084B (zh) 2021-09-10
AU2016328204A1 (en) 2018-04-19
EP3353213A1 (en) 2018-08-01
EP3353213A4 (en) 2019-05-29
KR101782487B1 (ko) 2017-09-27
CN113603785B (zh) 2024-01-05

Similar Documents

Publication Publication Date Title
MX2018003470A (es) Nuevo anticuerpo anti-mesotelina y composicion que comprende el mismo.
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
GEP20217260B (en) Antibody neutralizing human respiratory syncytial virus
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2014009909A (es) Acido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilacion para incrementar la expresion de un antigeno tumoral codificado.
EA201590986A1 (ru) Антитела к ceacam5 и их применения
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
PH12019500571A1 (en) Anti-pd-1 antibodies
NZ730450A (en) Binding molecules, especially antibodies, binding to l1cam (cd171)
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
PH12019501050A1 (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
PH12018501070A1 (en) Anti-pcsk9 antibody and use thereof
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
EA202090372A1 (ru) Универсальные соединения авт и их применение
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use